Symphogen, Biovitrum Receive Orphan Drug Designation

Symphogen and Swedish Orphan Biovitrum Wednesday announced that the United States Food and Drug Administration has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia.
Earth Times